Lyell Immunopharma to Present at Investor Conferences

Lyell Immunopharma, a late-stage clinical company, announced its participation in September investor conferences. The company's senior management team will present and participate in Morgan Stanley's 23rd Annual Global Healthcare Conference and H.C. Wainwright's 27th Annual Global Investment Conference. A live webcast of the presentation will be available on Lyell's website. Lyell is advancing next-generation CAR T-cell therapies for patients with cancer, including its lead product candidate, LYL314, for large B-cell lymphoma.

Lyell Immunopharma (Nasdaq: LYEL), a late-stage clinical company specializing in next-generation CAR T-cell therapies for cancer treatment, has announced its participation in two upcoming investor conferences in September 2025. The company's senior management team will present and participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8th at 9:15 AM ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 10th at 8:00 AM ET. Investors can access the live webcasts through Lyell's website, with replays available after the presentations [1].

Lyell Immunopharma is focused on advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. The company's lead product candidate, LYL314, is a dual-targeting CD19/CD20 CAR T-cell therapy designed to enhance complete response rates and prolong the duration of responses compared to existing CD19-targeted CAR T-cell therapies for large B-cell lymphoma. LYL314 is currently being evaluated in the PiNACLE trial, an ongoing single-arm pivotal trial for patients with large B-cell lymphoma that has relapsed or been refractory to two or more lines of prior therapy [1, 2].

The company's LyFE Manufacturing Center™ has commercial launch capability and can manufacture more than 1,200 CAR T-cell doses at full capacity. This capacity is crucial for supporting the ongoing and planned pivotal trials and potential commercial launch of LYL314 [1, 2].

Forward-looking statements in the press release include Lyell management's planned participation in the investor conferences, the potential clinical benefits and therapeutic potential of LYL314 for the treatment of large B-cell lymphoma, and the sufficiency of LyFE's capacity to manufacture drug supply for ongoing and planned trials and commercial launch. These statements are based on Lyell's current plans, objectives, and expectations and are subject to significant risks and uncertainties [1, 2].

References:
[1] https://www.stocktitan.net/news/LYEL/lyell-immunopharma-announces-participation-in-september-investor-2e2qdbrqhi1t.html
[2] https://www.globenewswire.com/news-release/2025/09/02/3143147/0/en/Lyell-Immunopharma-Announces-Participation-in-September-Investor-Conferences.html